Last reviewed · How we verify
LSTA1
At a glance
| Generic name | LSTA1 |
|---|---|
| Also known as | CEND-1, certepetide |
| Sponsor | Australasian Gastro-Intestinal Trials Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC (PHASE1, PHASE2)
- A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (PHASE2)
- CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (PHASE1, PHASE2)
- The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma (PHASE1, PHASE2)
- A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma (PHASE2)
- CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer (PHASE1)
- Intraperitoneal LSTA1 in CRS-HIPEC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |